Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Finally a vaccine for children as the regulator has given the go ahead for Serum Institute's Covovax for use &nbsp;children aged 7 to 11 years subject to certain conditions, official sources told news agency PTI.&nbsp;
The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.
Prakash Kumar Singh, director, Government and Regulatory Affairs at Serum Institute of India (SII) had submitted an application to DCGI in this regard on March 16, official sources had said.
''The SEC last week deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years,'' an official source said.
The expert panel, in its last meeting in April, had sought more data from the Pune-based firm over the application.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.
The country began inoculating children aged 12-14 years from March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.
The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.
India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.
The next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 years.
India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. Precaution dose of COVID-19 vaccines for all aged above 18 years began at private vaccination centres from April 10.

Covid vaccine Covovax gets nod for children 7-11 from Indian regulator: reports

Finally a vaccine for children as the regulator has given the go ahead for Serum Institute's Covovax for use in children aged 7 to 11 years subject to certain conditions, official sources told news agency PTI. 

Vaccine for 7-11 age group gets nod 

The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years

Finally a vaccine for children as the regulator has given the go ahead for Serum Institute's Covovax for use &nbsp;children aged 7 to 11 years subject to certain conditions, official sources told news agency PTI.&nbsp;
The DCGI's nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.
Prakash Kumar Singh, director, Government and Regulatory Affairs at Serum Institute of India (SII) had submitted an application to DCGI in this regard on March 16, official sources had said.
''The SEC last week deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years,'' an official source said.
The expert panel, in its last meeting in April, had sought more data from the Pune-based firm over the application.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.
The country began inoculating children aged 12-14 years from March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.
The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.
India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.
The next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 years.
India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. Precaution dose of COVID-19 vaccines for all aged above 18 years began at private vaccination centres from April 10.

Covovax has become the 4th Covid-19 vaccine to be approved in India for children above 12 years. Here is all you need to know about the Serum Institute manufactured vaccine.

It is a 2-dose protein-based Covid-19 vaccine developed by Novavax in the US
In August 2021, Novavax had given SII the licence to manufacture and supply the vaccine
The WHO has already cleared it and it has an Emergency Use Authorization
India approved Covovax for use in adults in December last year
First protein-based vaccine approved for use in 12-18 years age group in India
Covovax has reported an efficacy of 80% in 2,247 children aged 12-17 years
Covovax targets the spike protein on the surface of the SARS-CoV-2 coronavirus
Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them. 
Different from Covishield which uses a separate virus to carry the weakened spike protein to trigger an immunity response 


Explained: Covovax, the Covid-19 vaccine approved for 12-17 years age group

Covovax has become the 4th Covid-19 vaccine to be approved in India for children above 12 years. Here is all you need to know about the Serum Institute manufactured vaccine.
((GFX&nbsp;IN))
TEXT: 2-dose protein-based&nbsp;Covid&nbsp;vaccine developed by US firm Novavax
It is a 2-dose protein-based&nbsp;Covid-19&nbsp;vaccine developed by Novavax&nbsp;in the US
TEXT: Serum Institute manufacturing the vaccine as Covovax&nbsp;in India
In August 2021,&nbsp;Novavax had given SII the licence to manufacture and supply the vaccine
TEXT: Covovax&nbsp;has been cleared by the WHO
The WHO has already cleared it and it has an Emergency Use Authorization
TEXT: India approved Covovax&nbsp;for use in adults in Dec 2021
India approved Covovax for use in adults in December last year
TEXT: 1st protein based jab for 12-18 years age group in India
First protein-based vaccine approved for use in 12-17 years age group in India
TEXT: Efficacy of 80% in children aged 12-17 years: Novavax
Covovax&nbsp;has reported an efficacy of 80% in 2,247 children aged 12-17 years
TEXT: Covovax&nbsp;targets the spike protein on surface of Covid-19 virus
Covovax targets the spike protein on the surface of the SARS-CoV-2&nbsp;coronavirus
TEXT: Jab trains body to see copies of spike proteins as foreign substance
Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them.&nbsp;
&nbsp;

Covovax is the first protein-based vaccine approved for use in 12-17 years age group in India

Covovax has become the 4th Covid-19 vaccine to be approved in India for children above 12 years. Here is all you need to know about the Serum Institute manufactured vaccine.
<ul>
<li>It is a 2-dose protein-based&nbsp;Covid-19&nbsp;vaccine developed by Novavax&nbsp;in the US</li>
<li>In August 2021,&nbsp;Novavax had given SII the licence to manufacture and supply the vaccine</li>
<li>The WHO has already cleared it and it has an Emergency Use Authorization</li>
<li>India approved Covovax for use in adults in December last year</li>
<li>First protein-based vaccine approved for use in 12-17 years age group in India</li>
<li>Covovax&nbsp;has reported an efficacy of 80% in 2,247 children aged 12-17 years</li>
<li>Covovax targets the spike protein on the surface of the SARS-CoV-2&nbsp;coronavirus</li>
<li>Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them.&nbsp;</li>
<li>Different from Covishield&nbsp;which uses a separate virus to carry the weakened spike protein to trigger an immunity response&nbsp;</li>
</ul>
Also Watch|&nbsp;<a href="https://www.editorji.com/coronavirus/pandemic-over-omicron-last-variant-who-slams-fake-news-warns-against-covid-laxity-1647769319854" target="_blank">Pandemic over, Omicron last variant? WHO slams fake news, warns against Covid laxity</a>

The centre on Tuesday cleared two more Covid vaccines and one anti-viral drug to boost the fight against the pandemic.
The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used only in an emergency
Union Health Minister Mansukh Mandaviya on Tuesday said that the Central Drug Authority has approved the Serum Institute of India's Covid-19 vaccine Covovax, Biological E's jab Corbevax and anti-Covid pill Molnupiravir for restricted use in emergency situation.
The announcement comes a day after the Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation recommended granting emergency use authorisation to the Covid-19 vaccines Covovax and Corbevax with certain conditions.
It also had recommended granting restricted emergency use approval to the drug Molnupiravir for treatment of adult patients with Covid-19 and who have high risk of progression of the disease.
With this approval, the number of Covid vaccines which have received emergency use authorisation in the country has increased to eight.
Six Covid-19 vaccines -- Serum Institute's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's ZyCoV-D, Russia's Sputnik V and the US-made Moderna and Johnson and Johnson -- had already received approval from the Indian drug regulator earlier.

Covid-19: India clears 2 new vaccines - Corbevax & Covovax - and one oral pill

Covid-19: India clears 2 new vaccines - Corbevax & Covovax - and one oral pill. Know details

India clears 2 new Covid vaccines and one oral pill

India clears 2 new Covid vaccines&nbsp;and one oral pill
Corbevax &amp; Covovax&nbsp;jabs and Merck's Covid pill get nod
India's own vaccine Corbevax&nbsp;by Biological E cleared
Serum Institute's&nbsp;Covovax&nbsp;also gets Centre's clearance
Total of 8 Covid vaccines cleared by Indian govt so far&nbsp;

Covid&nbsp;Vaccines:&nbsp;The two latest shots cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used only in an emergency

The centre on Tuesday cleared two more Covid vaccines and one anti-viral drug to boost the fight against the pandemic.
The two latest vaccines cleared by India are Corbevax and Covovax. The anti-viral drug Molnupiravir can be used only in an emergency.
Union Health Minister Mansukh Mandaviya on Tuesday said that the Central Drug Authority has approved the Serum Institute of India's Covid-19 vaccine Covovax, Biological E's jab Corbevax and anti-Covid pill Molnupiravir for restricted use in emergency situation.
The announcement comes a day after the Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation recommended granting emergency use authorisation to the Covid-19 vaccines Covovax and Corbevax with certain conditions.
It also had recommended granting restricted emergency use approval to the drug Molnupiravir for treatment of adult patients with Covid-19 and who have high risk of progression of the disease.
With this approval, the number of Covid vaccines which have received emergency use authorisation in the country has increased to eight.
Six Covid-19 vaccines -- Serum Institute's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's ZyCoV-D, Russia's Sputnik V and the US-made Moderna and Johnson and Johnson -- had already received approval from the Indian drug regulator earlier.
Also Watch:&nbsp;<a href="https://www.editorji.com/coronavirus/covovax-explained-adding-another-weapon-to-india-s-covid-arsenal-1640674844863" target="_blank">Covovax Explained: Adding another weapon to India's Covid arsenal</a>&nbsp;

covovax vaccine

Categories